<DOC>
	<DOCNO>NCT00811798</DOCNO>
	<brief_summary>This study collect safety data GlaxoSmithKline Biologicals ' human papillomavirus ( HPV ) vaccine healthy female Chinese origin unable receive three dos commercially available HPV vaccine 25 year , placebo recipient primary study ( NCT00306241 ) .</brief_summary>
	<brief_title>Safety Study GSK Biologicals ' HPV Vaccine ( GSK-580299 ) Healthy Female Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects enrol primary study ( NCT00306241 ) receive placebo ( aluminium hydroxide [ Al ( OH ) 3 ] ) . A female unable receive three dos commercially available Cervarix 25th birthday . Written inform consent obtain subject ( prior enrolment ) . Healthy subject establish medical history clinical examination enter study . Subjects must negative urine pregnancy test . Subjects must nonchildbearing potential , subject childbearing potential , must abstinent ( , must document source document vaccination visit ) must use adequate contraception 30 day prior vaccination continue two month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Pregnant breastfeeding . Planning become pregnant likely become pregnant ( determined investigator ) planning discontinue contraceptive prevention study period two month last vaccine dose . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex ( find syringetip cap plunger ) . Known acute chronic , clinically significant neurologic , haematological , hepatic renal functional abnormality , determine previous physical examination laboratory test . Cancer autoimmune disease treatment . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Previous administration adjuvant use HPV16/18 vaccine . Previous vaccination HPV plan administration another HPV vaccine study . Acute disease time enrolment .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hong Kong</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>Safety</keyword>
</DOC>